<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4893">
  <stage>Registered</stage>
  <submitdate>24/07/2012</submitdate>
  <approvaldate>24/07/2012</approvaldate>
  <nctid>NCT01650701</nctid>
  <trial_identification>
    <studytitle>A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma</studytitle>
    <scientifictitle>A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.</scientifictitle>
    <utrn />
    <trialacronym>RELEVANCE</trialacronym>
    <secondaryid>2011-002792-42</secondaryid>
    <secondaryid>RV-FOL-GELARC-0683</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Follicular Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rituximab
Treatment: drugs - Lenalidomide
Treatment: drugs - Rituximab - CHOP
Treatment: drugs - Rituximab - CVP
Treatment: drugs - Rituximab - Bendamustine

Experimental: Lenalidomide + Rituximab - Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Active Comparator: Control -  ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.


Treatment: drugs: Rituximab
 Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Treatment: drugs: Lenalidomide
 Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

Treatment: drugs: Rituximab - CHOP
six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles

Treatment: drugs: Rituximab - CVP
eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,

Treatment: drugs: Rituximab - Bendamustine
six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>COMPLETE RESPONSE RATE - Complete response (CR/CRu) rate at 120 weeks Response evaluation was as defined by International Working Group (IWG) Response Criteria (Cheson 1999). Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms if present before therapy.</outcome>
      <timepoint>Timeframe: CR/CRu rate at 120 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - PFS is defined as the time from the start of study drug therapy to the 1st observation of disease progression or death due to any cause.</outcome>
      <timepoint>up to 13 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Treatment Failure (TTF)</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival (EFS)</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Next Anti-Lymphoma Treatment (TTNLT),</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Next Chemotherapy Treatment (TTNCT)</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate at 120 weeks by International Working Group (IWG) 1999 criteria</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health related quality of life as measured by the EORTC QLQ-C30</outcome>
      <timepoint>up to13 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed CD20+ follicular lymphoma grade 1, 2 or 3a

          -  Have no prior systemic treatment for lymphoma.

          -  Must be in need of treatment

          -  Bi-dimensionally measurable disease with at least one mass lesion &gt; 2 cm that was not
             previously irradiated.

          -  Stage II, III or IV disease.

          -  Must be = 18 years and sign an informed consent.

          -  Performance status = 2 on the ECOG scale.

          -  Adequate hematological function (unless abnormalities are related to lymphoma
             infiltration of the bone marrow)

          -  Willing to follow pregnancy precautions</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Clinical evidence of transformed lymphoma by investigator assessment or Grade 3b
             follicular lymphoma.

          -  Patients taking corticosteroids during the last 4 weeks, unless administered at a dose
             equivalent to &lt; 10 mg/day prednisone (over these 4 weeks).

          -  Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed
             consent.

          -  Known Seropositive for or active viral infection with hepatitis B virus (HBV),
             hepatitis C virus (HCV)or human immunodeficiency virus (HIV).

          -  Life expectancy &lt; 6 months.

          -  Known sensitivity or allergy to murine products.

          -  Prior history of malignancies, other than follicular lymphoma, unless the patient has
             been free of the disease for = 10 years.

          -  Prior use of lenalidomide.

          -  Neuropathy &gt; Grade 1.

          -  Presence or history of CNS involvement by lymphoma.

          -  Patients who are at a high risk for a thromboembolic event and are not willing to take
             venous thromboembolic (VTE) prophylaxis.

          -  serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) &gt; 3x upper
             limit of normal (ULN), except in patients with documented liver or pancreatic
             involvement by lymphoma

          -  total bilirubin &gt; 2.0 mg/dl (34 Âµmol/L) except in cases of Gilberts Syndrome and
             documented liver involvement by lymphoma

          -  creatinine clearance of &lt; 30 mL/min

          -  Pregnant or lactating females.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             patient at unacceptable risk if he/she were to participate in the study, or which
             confounds the ability to interpret data from the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1031</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Concord Repatriation General Hospital - Concord</hospital>
    <hospital>Nepean Hospital - Penrith</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <postcode> - Concord</postcode>
    <postcode> - Penrith</postcode>
    <postcode> - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden Wurtemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andaloucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Canarias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Mallorca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Marbella</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Lymphoma Academic Research Organisation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Celgene Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find out if lenalidomide when given along with rituximab can
      help to control the disease and also increase the length of your response (complete or
      partial response) compared to the standard of care rituximab chemotherapy treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01650701</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Franck Morschhauser, MD, PhD</name>
      <address>The Lymphoma Study Association (LYSA)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>